HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Bullfrog Kids UV Defender will be supported with print ads in parenting magazines coinciding with the product's launch early next year, Chattem reports during first annual investor call Nov. 11. Bullfrog Kids is debuting alongside three other new Bullfrog products, including a Surfer Gel (1"The Rose Sheet" Sept. 27, 2004, p. 6). Chattem also will support Bullfrog's other new products with radio ads intended to reach active adults and print ads to reach mothers, the firm notes. New skin care line ph20 by pHisoderm, which also is shipping in the first quarter, will initially roll out to about 2,800 stores nationwide, according to Chattem...

You may also be interested in...



Chattem Leaps Into 2005 With BullFrog, Phisoderm Extensions

Chattem is aiming to revitalize the pHisoderm brand with the launch of a new skin care line,pH20 by pHisoderm, early next year, the firm said

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel